Skip to main content

Table 1 Clinical and demographic characteristics of RA patients prior to pneumococcal vaccination

From: Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients

  RA control MTX group ABT group p Values between treatment groups
n = 35 n = 55 n = 21
Male/female 12/23 11/44 4/17 0.251
Age, mean ± SD (years) 70.5 ± 10.8 63.8 ± 11.5 59.8 ± 12.0 0.002
Weight, mean ± SD (Kg) 53.3 ± 9.5 52.9 ± 11.8 55.2 ± 10.1 0.501
BMI, mean ± SD 21.8 ± 3.5 21.7 ± 3.7 23.2 ± 4.9 0.344
RA duration, mean ± SD (years) 11.7 ± 12.5 14.1 ± 10.9 13.5 ± 11.2 0.144
MTX dose, mean ± SD (mg/week) - 7.8 ± 2.4 7.2 ± 3.4(15/21) -
ABT dose, mean ± SD (mg/4 week) - - 547.6 ± 127.9 -
Use of prednisolone, number of patients (%) 21 (60.0) 30 (54.5) 13(61.9) 0.798
Prednisolone dose, mean ± SD (mg/day) 6.06 ± 4.23 4.98 ± 2.97 5.04 ± 2.85 0.769
DAS28(CRP), mean ± SD 2.79 ± 1.17 2.61 ± 0.98 2.48 ± 1.31 0.565
SDAI, mean ± SD 9.03 ± 6.32 8.15 ± 7.33 8.32 ± 7.29 0.593
CDAI, mean ± SD 7.83 ± 5.40 7.46 ± 6.73 7.87 ± 6.54 0.721
IP (%) 6 (17.1) 7 (12.7) 3(14.3) 0.844
COPD (%) 3 (8.6) 1 (1.8) 2(9.5) 0.251
Smoking history (%) 10(28.6) 13(23.6) 6(28.6) 0.839
  1. Data were obtained immediately before pneumococcal vaccination. p values between treatment groups were determined using the Kruskal-Wallis test. p values were calculated with the chi-square test for qualitative data. RA rheumatoid arthritis, MTX methotrexate, ABT abatacept, BMI body mass index, DAS28 Disease Activity Score 28, SDAI simplified disease activity index, CDAI clinical disease activity index, IP interstitial pneumonia, COPD chronic obstructive pulmonary disease